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Toxoplasma gondii (T.gondii) is distributed worldwide and infects most species of
warm-blooded animals, including humans. Toxoplasmosis has serious consequences,
especially in people with an impaired or immature immune system. Thus, an effective
vaccine is urgently required. Secretory microneme proteins are essential for the adhesion
and invasion of T. gondii. The gene encoding the microneme protein, T. gondii
secreted protein with an altered thrombospondin repeat (TgSPATR), we constructed
a recombinant eukaryotic plasmid, pVAX1-TgSPATR, as a DNA vaccine, injected
it intramuscularly into BALB/c mice and evaluated the induced immune response.
Lymphocyte proliferation assays, cytokine (IFN-γ, IL-2, IL-4, IL-10), and antibody
determinations showed that mice immunized with pVAX1-TgSPATR produced humoral
and mixed Th1/Th2 type cellular immune responses. The survival times of mice
immunized with pVAX1-TgSPATR were also significantly prolonged (15.7 ± 1.42 days)
compared with control groups, which died within 7 days of challenge (p < 0.05).
The current study indicated that pVAX1-TgSPATR induce a T. gondii specific immune
response and might be a promising vaccine candidate against toxoplasmosis. To the
best of our knowledge, this is the first report to evaluate the immunoprotective value of
TgSPATR against T. gondii.
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INTRODUCTION
Toxoplasma gondii, of the phylum Apicomplexa, is an obligate intracellular parasite capable of
infecting almost all species of warm-blooded animals, including humans (Lehmann et al., 2003;
Piña-Vázquez et al., 2008). Although the primary infection is usually asymptomatic, toxoplasmosis
still causes serious health issues for pregnant women, in which congenital infection can cause
miscarriages, congenital diseases or other defects (Kravetz and Federman, 2005; Rorman et al.,
2006). Additionally, toxoplasmosis can affect all types of livestock and causes serious economic
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losses to industry. Infected domestic animals are another route
of transmission to humans (Dubey et al., 2005; Dautu et al.,
2007; Zou et al., 2009). Thus, finding an effective vaccine against
T. gondii is an important and realistic goal, which would be
beneficial to both the humans and the farming industry.
In previous research, there were several kinds of vaccines
have been tested their immunoprotective effects against
toxoplasmosis, including attenuated vaccines, genetically
engineered vaccines and DNA vaccines (Wang et al., 2007; Kur
et al., 2009). Nonetheless, few of them have been authorized
to use, mainly because of the low level of immune protection
or biosafety issues (Innes and Vermeulen, 2006). Former study
showed that inactivated vaccines could only provide moderate
levels of protection. There is a commercial attenuated vaccine
(ToxoVax R©, Intervet B.V.) has been used in some areas, but the
side effects as well as the expensive price all have limited the
use of this vaccine (Mateus-Pinilla et al., 1999). In this context,
we focus on the research of DNA vaccines, because these types
of vaccines have been demonstrated to effectively induce both
the long-term humoral and cellular immune responses against
toxoplasmosis in animal models (Robinson, 1999; Gurunathan
et al., 2000).
In recent years, great advancement has been made in the
identification of vaccine candidates against T. gondii infection
that could elicit a protective immune response (Jongert et al.,
2008; Boothroyd, 2009).
In these potential vaccine antigens, T. gondii secreted
protein with an altered thrombospondin repeat (TgSPATR)
appears particularly promising. TgSPATR was a new member
in microneme protein family, Ca2+-dependently secreted during
early stage of invasion and existed on the outer surface
of parasites (Kawase et al., 2010). This antigen is the
homolog of Plasmodium falciparum SPATR (PfSPATR) which is
immunogenic and recombinant SPATR antibodies could block
sporozoite invasion (Chattopadhyay et al., 2003; Mahajan et al.,
2005). Recent studies have shown that TgSPATR is contributed
to T. gondii invasion and virulence. 1spatr parasites were ∼50%
reduced in invasion compared to parental strains, a defect that
was reversed in the complemented strain. In mouse virulence
assays,1spatr parasites were significantly attenuated, with∼20%
of mice surviving infection (Huynh et al., 2014). These findings
demonstrate that TgSPATR may be a good vaccine candidate.
However, there have been no studies evaluating the potential
of TgSPATR as a vaccine candidate against T. gondii. The purpose
of this research was to detect the immunogenicity and protective
value of TgSPATR in mice. We constructed a eukaryotic plasmid
expressing TgSPATR and injected BALB/c mice intramuscularly
to assess the immunoprotective effect of this DNA vaccine against
the infection with the high virulence T. gondii RH strain in a
BALB/c mouse model.
MATERIALS AND METHODS
Mice and Parasites
Seven-week-old BALB/c mice were purchased from the
Experimental Animal Center of Zhejiang Academy of Medical
Sciences, China. All mice were maintained under standard
conditions and the experimental procedures were in accordance
with Chinese legislation on the use and care of laboratory
animals.
Tachyzoites of the highly virulent T. gondii (type I) RH
strain were maintained in our laboratory through serial passage
in human foreskin fibroblast cells (HFF) grown in Dulbecco’s
modified Eagle’s medium (DMEM) (Gibco, Carlsbad, CA,
USA), supplemented with 5% fetal bovine serum (FBS) (Gibco,
Carlsbad, CA, USA).
ETHICS STATEMENT
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee (IACUC) of Zhejiang Academy of Medical Sciences
(Permit number: IACUC 2005-31).
Construction of the Eukaryotic Expression
Plasmid
The TgSPATR open reading frame was amplified by polymerase
chain reaction (PCR) from genomic DNA of T. gondii RH strain,
using the following primers: sense primer : 5′-AAGCTTATG
GAGGTTTCAAGAAGTCA-3′; antisense primer: 5′-GAATTC
TTAAGACGAAGGCTGATTGC-3′, which introduce the
HindIII and EcoRI restriction sites (underlined), respectively.
The TgSPATR fragment was ligated into vector pVAX1
(Invitrogen, Carlsbad, CA, USA), digested with HindIII and
EcoRI endonucleases, to construct the pVAX1-TgSPATR
plasmid. To identify the positive plasmids, the recombinant
plasmids were screened by PCR, double restriction enzyme
digestion and DNA sequencing.
Purification of pVAX1-TgSPATR and
Transfection Cells
pVAX1-TgSPATR was purified from transformed Escherichia coli
DH5α, using an Endofree plasmid giga kit (Qiagen, Chatsworth,
CA, USA), dissolved in sterile endotoxin-free phosphate-buffered
saline (PBS) and stored at −20◦C. The DNA concentration was
determined by absorbance at 260 nm using a NanoDrop 2000.
Plasmid expression was analyzed by transfection of HEK293
cells using lipo2000 reagent (Invitrogen, Carlsbad, CA, USA),
according to the manufacturer’s instructions. After 2 d, cell
monolayers and supernatants were collected and stored at
−20◦C. Expression of TgSPATR in the transfected cells was then
analyzed by RT-PCR and western blotting.
Western Blotting Analysis of TgSPATR
The cell lysates and purified rTgSPATR were separated by
polyacrylamide gel electrophoresis and transferred onto PVDF
membranes. Both cell lysates and purified rTgSPATR were
probed with 1:100 dilutions of rabbit anti-T. gondii sera. Bound
antibodies were detected using a horseradish peroxidase (HRP)-
labeled goat anti-rabbit IgG, and the color was developed using
tetra-methylbenzidine (TMB) (Sigma,St. Louis, MO, USA).
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Immunization Schedule and Challenge
Infection
Four groups of BALB/c mice (n = 15 each) were injected
intramuscularly with 100 µg of pVAX1-TgSPATR plasmid DNA
suspended in 100 µl sterile PBS in the thigh skeletal muscle
(50 µl in each thigh skeletal muscle), whereas control groups
mice received PBS, blank pVAX1 vector or nothing. Group I
was injected with nothing as a blank control, group II with PBS
(100 µl/each) alone as a control, group III with empty pVAX1
vector (100 µg/each) also as control, and group IV with pVAX1-
TgSPATR. All groups were boosted with the same dose twice
more with a 2-week interval.
Two weeks after the last booster injection, all the mice were
challenged intraperitoneally with 100 tachyzoites of the virulent
T. gondii RH strain. Blood was obtained from the mouse tail vein
from mice in each group before each immunization at weeks 0,
2, and 4, and 2 weeks after the last booster (week 6). The serum
was separated from the blood cells by centrifugation and stored
at −20◦C until used. Pre-immune serum samples were used as
negative controls.
Evaluation of Humoral Responses
Antigen-specific IgG antibodies were analyzed by ELISA using
a standard procedure (Du and Wang, 2005). Briefly, 96-well
micro-titer plates were coated overnight at 4◦C with soluble
tachyzoite antigens (STAg, 1 µg/well). The plates were washed
three times with PBS containing 0.05% Tween-20 (PBST), pH
7.4. Nonspecific binding sites were blocked with PBS containing
10% BSA and incubated with mouse sera diluted 1:100 for 1 h
at 37◦C. After washing the plates in PBST, the bound antibodies
were detected by HRP-conjugated goat anti-mouse IgG, IgG1,
and IgG2a (Abcam, Cambridge, UK) diluted 1:10,000. Immune
complexes were revealed with TMB as the substrate. The optical
density (OD)wasmeasured at 450 nmusing an ELISAmicroplate
reader (Bio-Rad 680, USA). For each serum sample, the assay was
run in duplicate.
Splenocyte Proliferation by the MTT Assay
Two weeks after the final booster injection, spleens were
harvested from five mice in each group. Splenocyte suspensions
were prepared and cultured in 96-well plates in triplicate at the
density of 2 × 105 cells/well in DMEM medium supplemented
with FBS. Thereafter, the cultures were stimulated with either
10 µg/ml STAg, 5 µg/ml concanavalin A (Con A) (Sigma, St.
Louis, MO, USA) as a positive control or medium alone as a
negative control. The plates were incubated in 5% CO2 at 37
◦C
for 68 h, before adding 50 µl of methyl thiazolyltetrazolium
(MTT) (Sigma,St. Louis, MO, USA) solution to each well and
incubating for 4 h. When the incubation was finished, 200 µl
DMSO was added to each well before all the contents were
discarded, and the absorbance was evaluated at 450 nm using
an ELISA reader. The results were expressed as the stimulation
index (SI), which is the ratio of the average OD450 value of
the experimental samples containing antigen-stimulated cells to
the average OD450 value of control cells cultured with medium
alone.
Cytokine Analysis
To detect cytokines, spleen cells were obtained and cultured as
described in the lymphocyte proliferation assay. The cell-free
supernatants from cultured splenocytes were collected after 24,
72, and 96 h of different stimulations to analyze their interleukin-
2 (IL-2) and interleukin-4 (IL-4), interleukin-10 (IL-10), gamma-
interferon (IFN-γ) contents, respectively. The IL-2, IL-4, IL-10
and IFN-γ concentrations were evaluated using a commercial
ELISA kit (eBioscience,San Diego, CA, USA) according to
the manufacturer’s instructions. All assays were performed in
triplicate.
Statistical Analysis
Statistical analysis was carried out using one-way ANOVA for
proliferation and cytokines production assays. The survival time
was analyzed using the Kaplan-Meier method. Statistical analysis
and graphics were carried out using SPSS software (SPSS Inc.,
Chicago, IL, USA). The results of the comparisons between
groups were considered significantly different if p< 0.05.
RESULTS
The Expression of pVAX1-TgSPATR
Plasmid in HEK293 Cells
The TgSPATR gene was successfully amplified by PCR, ligated
into the pVAX1 plasmid and produced in E. coli DH5α cells. In
addition, western blotting analysis showed a specific band with a
molecular mass of 55kDa, which is similar to the predicted mass
in T. gondii, in HEK293 cells transformed with pVAX1-TgSPATR
(Figure 1). The results demonstrated that the pVAX1-TgSPATR
plasmid could express the target antigen in HEK293 cells.
Specific IgG and IgG Isotypes Induced by
Vaccination
To detect the levels of anti-T. gondii antibodies, the sera samples
were tested by ELISA. The results are shown in (Figure 2A).
The specific anti-TgSPATR antibodies titers were detectable as
early as 2 weeks post-inoculation in the group immunized
pVAX1-TgSPATR. During the test period, the level of the specific
antibodies increased with successive immunizations and showed
were significantly higher at the end of the test period compared
FIGURE 1 | Western blot analysis of TgSPATR expressed in HEK293.
M: marker 40–70 kDa; (1) negative control, the lysate of HEK293 transformed
with empty pVAX1 vector; (2) the lysate of HEK293 transformed with
pVAX1-TgSPATR; (3) purified rTgSPATR of T. gondii expressed in E. coli.
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FIGURE 2 | Specific antibody responses induced by DNA immunization with pVAX1-TgSPATR, pVAX1, PBS and blank control, as assessed by ELISA.
(A) Determination of specific anti-TgSPATR antibodies in the sera of BALB/c mice. Serum samples were collected at 0, 2, 4, and 6 weeks post-primary immunization.
(B) Determination of the specific anti-TgSPATR IgG subclass profile in the sera of immunized BALB/c mice. Results are expressed as means of the OD450 value and
the standard deviation (n = 10); statistically significant differences (p < 0.05) are indicated by an asterisk (*).
with the other three former time points [p < 0.05; up to 0.66 ±
0.07 (mean± S.D.)]. Mice injected with PBS or pVAX1 and blank
control group did not generate significant antibody titers (p >
0.05).
Both IgG1 and IgG2a were found in the sera of mice
immunized with pVAX1-TgSPATR and a relative increased ratio
of IgG2a to IgG1 was observed (p < 0.05) (Figure 2B). No
significant change was found in the control groups.
In vitro Splenocyte Proliferation
The splenocytes from mice immunized with PBS, pVAX1,
pVAX1-TgSPATR and blank control were prepared 2 weeks after
the third immunization to assess the proliferative response. As
shown in Table 1, the level of splenocyte proliferation in the
group of mice injected with pVAX1-TgSPATR was higher than
those of the other groups (p < 0.05); there was no remarkable
change in the control groups. In addition, splenocytes from
all experimental and control groups proliferated to comparable
levels in response to the mitogen ConA (data not shown).
Cytokine Production
The supernatants of splenocytes cultured from all groups of
mice were harvested at different times after the re-stimulation
with STAg and assessed for the production of cytokines of
IFN-γ, IL-2, IL-4, and IL-10. Table 1 shows that splenocytes
from mice immunized with pVAX1-TgSPATR secreted relatively
large amounts of IFN-γ, IL-2, IL-4, and IL-10. In particular,
significantly high levels of IFN-γ and IL-2 were detected in
spleen cell cultures from mice injected with pVAX1-TgSPATR
compared with groups immunized with the PBS, pVAX1
or the blank control (p < 0.05). Meanwhile, the levels of
IL-4 and IL-10, which are Th2-type cytokines, were also
significantly higher in the splenocytes of mice immunized with
pVAX1-TgSPATR, compared with the other three groups (p <
0.05). The observation was correlated with the findings above
that immunization with pVAX1-TgSPATR produced a mixed
Th1/Th2 type response, which further confirmed the results of
the IgG subclasses.
Protective Efficacy of DNA Vaccine in Mice
against Lethal Toxoplasmosis
To determine whether the pVAX1-TgSPATR could induce a
protective effect against T. gondii RH strain infection, immunized
mice were challenged with 100 tachyzoites 2 weeks after the last
immunization and their survival times were recorded (Figure 3).
No difference was observed among the groups immunized with
PBS, empty vector pVAX1 or blank control, all the mice in these
three control groups died by the 7th day after infection. However,
themice immunized with pVAX1-TgSPATR showed an increased
survival time (15.7 ± 1.42 days) compared with the control
groups (p< 0.05).
DISCUSSION
DNA vaccinations have been shown to be a promising approach
to protect animals and humans against pathogens, especially
intracellular parasites, due to their low cost of production,
thermal stability, and the ability to induce a wide range of cellular
and humoral immune responses (Chen et al., 2013).
In the past few years, encouraging progress has been made in
research into DNA vaccines against T. gondii infection. DNA-
based plasmid vaccines could elicit humoral as well as cellular
immunity and many have been developed and tested (Sharma
and Khuller, 2001). In this study, we used the plasmid pVAX1TM
as the vector, which contains appropriate genetic elements (e.g.,
promoter) required for in vivo expression of the antigen gene of
interest in the target organism and meets U.S. Food and Drug
Administra-tion (FDA) guidelines for design of DNA vaccines.
For instance, secretory microneme proteins are essential for
adhesion and invasion during the attachment to the host cell
surface (Beghetto et al., 2005). Using the MIC3 and MIC6
genes as DNA vaccines, the survival time of mice immunized
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TABLE 1 | Cytokine production and the proliferative responses of splenocytes from BALB/c mice immunized with PBS, pVAX1, pVAX1-TgSPATR, or blank
control.
Groups (n = 5) Cytokine production (pg/ml)a Proliferation(SI)b
IFN-γ IL-2 IL-4 IL-10
Blank control 44.23 ± 1.92 45.80 ± 1.73 48.99 ± 0.79 48.54 ± 0.12 0.64 ± 0.05
PBS 47.28 ± 2.34 43.43 ± 2.31 48.98 ± 3.28 49.36 ± 0.11 0.62 ± 0.01
pVAX1 44.11 ± 1.82 46.32 ± 3.26 49.19 ± 1.30 49.08 ± 0.03 0.55 ± 0.02
pVAX1-TgSPATR 672.87 ± 8.35* 367.93 ± 10.30* 212 ± 7.42* 261.8 ± 10.03* 1.24 ± 0.14*
aValues for IL-2, IL-4, IL-10 and IFN- γ are for 24, 24, 72, and 96 h, respectively.
bSI stands for stimulation index. Splenocytes from mice were harvested 2 weeks after the last immunization. Data are presented as the mean ± S.D. (n = 5). Three independent
experiments were performed.
*p < 0.05 compared with the control groups.
FIGURE 3 | Survival curves of BALB/c mice after challenge. Survival
curves of BALB/c mice injected with PBS, pVAX1, pVAX1-TgSPATR and the
blank group, challenged with 100 tachyzoites of T. gondii RH strain 2 weeks
after the last immunization. Each group comprised 10 mice. Statistically
significant differences (p < 0.05) are indicated by an asterisk.
with these DNA vaccines was significantly prolonged, while the
control groups died in less than a week (Fang et al., 2009;
Peng et al., 2009). In addition, ROP18 showed a promising
immunoprotective value as a DNA vaccine. The survival time
of mice immunized with pVAX1-ROP18 was significantly
prolonged around 27.9 ± 15.1 days compared with the control
groups, which were only survived 7 days after infection (Yuan
et al., 2011). Another vaccine, pcDNA3.1-HisGRA6, helped to
offer protective efficacy against toxoplasmosis and maintained
40% survival of BALB/c mice challenged with high virulence T.
gondii RH strain (Sun et al., 2011). However, although these DNA
vaccines presented a good protective effect against toxoplasmosis,
they could not fully protect the mice from death. Thus, DNA
vaccines with improved efficacy are required.
Thrombospondin-related anonymous protein (TRAP), one of
the type 1 transmembrane protein, plays an important role in cell
invasion and gliding motility by Plasmodium sporozoites (Sultan
et al., 1997; Kappe et al., 1999). In the sporozoite stage, this kind
of protein is expressed on the surface of cell and is associated with
invasion into liver cells. This protein contains a Thrombospondin
type 1 repeat domain (TSR), which is involved in cell attachment,
mobility as well as extracellular protease activities (Mahajan et al.,
2005). TSR domain appears in several kinds of surface proteins in
Plasmodium spp., and proteins with this domain are important
components of the invasion machinery. The thrombospondin-
related anonymous proteins containing TSR domains are now
mostly undergoing clinical trials as candidate vaccines (Alonso
et al., 2004; Mahajan et al., 2005).
Several experiments showed that sera from clinically immune
adults could recognize PfSPATR, while the serum from
volunteers with low levels of anti-sporozoite antibodies and from
control groups failed to recognize the antigen, which indicated
that the host immune system could recognize PfSPATR and the
reaction is specific. In addition, the anti-PfSPATR antibodies have
been demonstrated to inhibit the sporozoite invasion of human
liver cells, which also indicated the value of an SPATR vaccine
(Menard et al., 1997; Chattopadhyay et al., 2003).
In T. gondii, TgSPATR also contains a TSR domain and it
is a homolog of Plasmodium SPATRs; therefore, it might have
similar functions to PfSPATR. Previous research found that
TgSPATR was secreted and shed from the parasite surface at the
early stage of invasion, in a Ca2+-dependent manner, as a new
microneme protein, and played an important role in parasite
adhesion and invasion (Nagamune et al., 2008; Kawase et al.,
2010). Knocking out the TgSPATR gene reduced invasion by
nearly 50% compared to parental strains, which was restored in
the complemented strain. In the virulence assays ofmousemodel,
1spatr parasites were significantly attenuated, with ∼20% of
mice surviving infection (Huynh et al., 2014). These observations
prompted us to test TgSPATR as a potential candidate vaccine
and drug target.
Therefore, we constructed the pVAX1-TgSPATR plasmid to
test its immune protective effect. After the last boost, the mice
immunized with pVAX1-TgSPATR had a relatively high level
of splenocyte proliferation compared with control groups (p <
0.05). To characterizing the immune response, we chose IFN-γ,
IL-2, IL-4, IL-10, and IgG2a and IgG1 isotypes as indicators of
Th1 and Th2 responses. Both IgG2a (Th1) and IgG1 (Th2) were
detected in immunized mice, with a slight increase in the anti-
TgSPATR of IgG2a compared with IgG1 isotype (Figure 2B).
In addition, the cellular immune response was associated with
the production of IFN-γ and interleukin cytokines. From the
cytokines results, a large amount of IFN-γ and IL-2 was
produced. Meanwhile, the levels of IL-4 and IL-10, which are
Th2-type cytokines, were also produced in significant amounts
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from the splenocytes of mice immunized with pVAX1-TgSPATR,
compared with the three control groups (p < 0.05) (Table 1).
These results indicated that pVAX1-TgSPATR triggered a mixed
Th1/The2 type immune response. The high level of IFN-γ was
similar to that noted in a previous study, where IFN-γ was the
key cytokine in resistance against T. gondii infection (Dautu et al.,
2007). The experimental results demonstrated that vaccination
with pVAX1-TgSPATR was capable of enhancing the immune
response in against T. gondii infection.
The survival rate of vaccinated mice against T. gondii
challenge infection is considered the most direct consideration
for assessing a candidate vaccine; therefore, we evaluated the
protection by infecting the vaccinatedmice intraperitoneally with
tachyzoites of T. gondii RH. Although the mice did not survive
after the infection, the mice immunized with pVAX1-TgSPATR
did show a significantly prolonged survival time compared with
those immunized with PBS, pVAX1 or blank control. The average
survival time of the pVAX1-TgSPATR immunization group was
15.7 ± 1.42 days, while the control groups all died by the 7th
day after infection (p < 0.05). The results indicated that the
TgSPATR had the potential to be a new DNA immunization
candidate. Ultimately, TgSPATR could be developed as a more
effective vaccine by immunizing with the appropriate vaccine
adjuvants, combining it with other effective DNA vaccines to
produce multiantigenic DNA vaccines or using prime-boost
strategy (Dziadek et al., 2011; Yuan et al., 2011; Quan et al., 2012).
In the present study, we found that immunization with
TgSPATR DNA vaccine helps the mice survive longer
significantly, but the mice were not capable of fighting high
dosage of the lethal T. gondii parasite high virulent strain
RH. However, our analysis may have been inappropriate
for the assessment of protection. In future experiments, it
would be helpful to validate the efficacy of spatr DNA vaccine
immunization by comparing the survival rate in vaccinated and
control groups using low virulence strains of T. gondii.
In conclusion, our study evaluated the immunogenicity and
protective effect of a novel DNA vaccine expressing TgSPATR.
Using the T. gondii spatr gene as a DNA vaccine, we were
able to elicit a mixed Th1/Th2 type immune response, with
high production of IFN-γ, IL-2, IL-4, and IL-10 in response
to T. gondii infection. Moreover, the survival time increased
significantly after the experimental challenge infection, all of
which indicated that TgSPATR is a promising candidate vaccine
against T. gondii infection.
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